Citigroup is set to report earnings before the bell

Citigroup is set to report earnings before the bell


Chief executive officer of Citigroup Jane Fraser visits FOX Business Network’s “Mornings With Maria” at Fox Business Network Studios on May 29, 2025 in New York City.

John Lamparski | Getty Images

Citigroup is scheduled to report fourth-quarter earnings before the opening bell Wednesday.

Here’s what Wall Street expects:

  • Earnings: $1.67 a share, according to LSEG
  • Revenue: $20.72 billion, according to LSEG
  • Net Interest Income: $14.85 billion, according to StreetAccount
  • Trading Revenue: Fixed income of $3.31 billion, equities of $1.19 billion, according to StreetAccount

Under CEO Jane Fraser, Citigroup is in the midst of a restructuring, selling off parts of its overseas operations, while also benefitting from U.S. banking deregulation.

Those are the reasons Wells Fargo banking analyst Mike Mayo calls Citigroup his top pick among bank stocks.

Analysts will be keen to hear whether Fraser sees momentum from last year carrying over into 2026.

On Tuesday, JPMorgan Chase posted results that exceeded expectations on better-than-expected trading revenue. Bank of America and Wells Fargo are also releasing Q4 results Wednesday, while Goldman Sachs and Morgan Stanley are scheduled for Thursday.

This story is developing. Please check back for updates.



Source

Inside the booming business of wellness third spaces and membership clubs
Business

Inside the booming business of wellness third spaces and membership clubs

A few years ago, Grace Guo began to crave places in New York City where hanging out with friends didn’t have to involve alcohol. Newly sober and surrounded by friends who also chose not to drink, Guo said she wanted alternatives to the typical social scene. After some research, she landed on Bathhouse and Othership: […]

Read More
FDA vaccine head will step down in April after string of controversial decisions
Business

FDA vaccine head will step down in April after string of controversial decisions

The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. Nathan Posner | Anadolu | Getty Images A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the […]

Read More
FDA reversals leave investors worrying about the fates of other experimental drugs
Business

FDA reversals leave investors worrying about the fates of other experimental drugs

Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration.  The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from […]

Read More
Powered by WordPress | WP Magazine by WP Mag Plus